Hangzhou Sciwind Biosciences Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-34
RECRUITING4
READOUTS ≤12 MONTHS3
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| ecnoglutide tablets NCT07243171 |
P1/2 | Recruiting | Overweight and/or Obesity; Weight Management | 126 | 2027-01-05 |
| XW003 injection NCT07073417 |
P2 | Active, not recruiting | Obesity; Weight Management | 163 | 2027-02-27 |
| ecnoglutide tablet NCT07929298 |
P2 | Not yet recruiting | Overweight , Obesity; Weight Management | 180 | 2027-09-03 |
| XW003 injection NCT07387094 |
P3 | Recruiting | OSA - Obstructive Sleep Apnea; Obesity | 140 | 2027-12-16 |
| Ecnoglutide Injection NCT07734311 |
P3 | Recruiting | Knee Osteoarthritis; Obesity | 360 | 2028-05-31 |
| Ecnoglutide Injection NCT07836270 |
P3 | Not yet recruiting | Adolescents With Obesity; Adolescents With Overweight & Weight-related Comorbidities | 192 | 2028-06-08 |
| XW003 injection NCT07434050 |
P3 | Recruiting | OSA - Obstructive Sleep Apnea; Obesity | 140 | 2028-06-19 |